We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Croatian regulators have approved the publication in the country’s major national newspapers of Barr Laboratories’ offer for Croatian generic drug firm Pliva, permitting the company to announce terms of the bid to Pliva shareholders.
The board of directors of Bristol-Myers Squibb (BMS) announced that an internal probe has unearthed no evidence the company engaged in illegal conduct while it and sanofi-aventis negotiated a patent settlement with Apotex over their blockbuster blood thinner Plavix.
The Dutch company Akzo Nobel announced Aug. 15 that it will call a general meeting of its shareholders to vote on whether to spin off Organon, the firm’s pharmaceutical business.
Shire Pharmaceuticals has agreed to drop a lawsuit against Barr Laboratories as part of a patent settlement involving Shire’s extended-release attention-deficit/hyperactivity disorder drug Adderall XR, the companies said Aug. 14.
Apotex’s decision to launch its generic version of the blockbuster blood thinner Plavix long before a court decides if it has a valid patent challenge may not be as risky as it first seemed, according to newly released details of its settlement agreement with sanofi-aventis and Bristol-Myers Squibb (BMS).
State attorneys general have refused to grant antitrust clearance for sanofi-aventis and Bristol-Myers Squibb (BMS) to pay Apotex to delay market entry of a generic version of the blood thinner Plavix.
The Department of Justice’s (DOJ) Antitrust Division has launched a criminal investigation into a proposed patent settlement between Bristol-Myers Squibb (BMS), sanofi-aventis and Apotex regarding the blood thinner Plavix, BMS announced July 27.